• Explore /
  • Poster
  • / Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).

Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).

Abstract Poster

Authors

null

Neal D. Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Neal D. Shore , Mark A. Preston , Justin R. Gregg , Simpa Samuel Salami , Ashley Ross , Amanda Bruno , Shankar Srinivasan , Niculae Constantinovici , Jorge A. Ortiz , Frank Verholen , Rana R. McKay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Hormone-Sensitive

Clinical Trial Registration Number

NCT05059236

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5111)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5111

Abstract #

TPS5111

Poster Bd #

285a

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Andrew J. Armstrong

First Author: Neal D. Shore

First Author: Fumihiko Urabe